STUDY: Keytruda + mRNA-4157 (V940) Vaccine Reduced Risk of Severe Melanoma Recurrence
In an investor news release from December 2023, Moderna and Merck shared follow-up data from the Phase 2b KEYNOTE-492/mRNA-4157-P201 clinical trial. During the trial, researchers explored the impact of Keytruda…